Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
A randomized double-blind, placebo-controlled cross-over phase II treatment trial of inhaled OligoG CF-5/20 for 28 days in subjects With Cystic fibrosis (CF) using Aztreonam due to chronic colonization With Burkholderia spp.
Primary outcome measures:
Changes in Burkholderia spp. density in expectorated sputum and/or induced sputum.
Conclusion:
OligoG CF-5/20 demonstrated a favorable safety profile. The potential to reduce Burkholderia suggests that further investigation of OligoG for treating infections in [Cystic fibrosis (CF)](br…